Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

123.99 -0.22 (-0.18%)
Streaming Delayed Price Updated: 2:38 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
47 48 Next >
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028
Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory... 
Via SBWire
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. 
Via Investor's Business Daily
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
How Is The Market Feeling About Novartis?
 
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Novartis Hikes Its Earnings Outlook For The Third Time This Year
The company also beat third-quarter expectations after spinning off its Sandoz unit. 
Via Investor's Business Daily
Diversifying Your Portfolio With Plant-Based Options
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... 
Via Talk Markets
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector. 
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Earnings Outlook For Novartis
 
Via Benzinga
Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug
Patients had big decreases in LDL cholesterol. But there were some side effects. 
Via Investor's Business Daily
3 Spectacular High-Yield Dividend Stocks to Buy in November
Income investors should find plenty to like with these stocks. 
Via The Motley Fool
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patients with IgA nephropathy (IgAN).  IgAN is a major cause of... 
Via Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
The U.S. 
Via Benzinga
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
2 Green Flags and 1 Red Flag for Novartis Stock
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes. 
Via The Motley Fool
7 Undervalued Stocks to Buy Before Everyone Else
Buy these undervalued stocks while they trade at a significant discount compared to their intrinsic valuations. 
Via InvestorPlace
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating. 
Via Investor's Business Daily
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline
According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,... 
Via SBWire
Avenue Z Hires Leading Digital Media and Technology Executive David Corchado to Lead Team in Global Strategy
--News Direct-- 
Via News Direct
US Stock Futures Surge Ahead Of Microsoft, Google Earnings: Analyst Says 'Magnificent Seven' Unlikely To See Tesla-Like Volatility After Results
Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day losing streak in the previous session. The uptick in... 
Via Benzinga
Topics Bonds Stocks
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Novartis AG (NYSE: NVS) reported  
Via Benzinga
Topics Earnings
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises. 
Via Benzinga
Topics Stocks
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
2 Biotech Stocks That Could Make You Richer
These two well-known drugmakers still have some growth fuel in their seemingly empty tanks. 
Via The Motley Fool
3 Unstoppable Stocks to Buy and Hold for Decades
These stocks can be pillars for your long-term portfolio, and investing in all three offers excellent diversification. 
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.